TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04653870

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: lumber decompression
Description: Group B: In group B patients were treated with conservative therapy (hot pack, Kaltenborn soft tissue techniques and home plan) and Decompression Session.~Conservative therapy: Same as Group A~Lumbar spine decompression:~30 Minutes Session (generalized time for every one) . On the account of MRI description level is recommended and acknowledged by MRI the level of disc protrusion, decompression is operated. Patient is lying on table facing upward. For locking of the patient's body it was secured by pelvis and thoracic straps. One part of the decompression table is immobile other is movable. Bottom extreme part of the table is mobile.~Estimation of weight of patient is first thing to do. We calculated it by division of whole weight by 5 and that 5th segment of weight was utilized as an interventional pound for decompression. .
Study: NCT02653144

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Description: local anesthetics adjuvants. Ropivacaine 0.5% 20ml. pre-operative single shot interscalene nerve block under ultrasound guidance and peripheral nerve stimulation in patients undergoing ambulatory shoulder surgery

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: local anesthetics adjuvants. Ropivacaine 0.5% 20ml. pre-operative single shot interscalene nerve block under ultrasound guidance and peripheral nerve stimulation in patients undergoing ambulatory shoulder surgery

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: local anesthetics adjuvants. 75mcg of dexmedetomidine. pre-operative single shot interscalene nerve block under ultrasound guidance and peripheral nerve stimulation in patients undergoing ambulatory shoulder surgery

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: local anesthetics adjuvants. 4mg dexamethasone. pre-operative single shot interscalene nerve block under ultrasound guidance and peripheral nerve stimulation in patients undergoing ambulatory shoulder surgery
Study: NCT04152070

Intervention type: OTHER
Intervention: No intervention
Description: There was no intervention to be administered, only collection of data through various tests and questionnaires.
Study: NCT02746978

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Peer directed education
Description: No drug or device is included. The intervention of interest is the redesigned approach to inpatient education that follows the Stanford chronic disease self management approach which includes peer-led problem solving discussions compared to traditional didactic education lectures provided by nurse educators

Intervention type: OTHER
Group type: OTHER
Intervention: Patient Engagement Portal
Description: No drug or device interventions. The Engagement Portal is populated by electronic medication record information (demographics, medications, supplies) then owned/maintained by patient after discharge. This approach to managing information and conditions associated with injury will be compared to the traditional approach of providing patients with a large instruction manual to carry home with them.
Study: NCT03547011

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: US guided Quadratus Lumborum block
Description: Patients will receive ultrasound guided quadratus lumborum block with 0.3 ml /kg bupivacaine 0.25% on each side with catheter insertion for maintenance doses 0.1ml/kg/hr on each side.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: US guided Paravertebral block.
Description: Patients will receive ultrasound guided thoracic paravertebral block with 0.3 ml/kg bupivacaine 0.25 % on each side with catheter insertion for maintenance doses 0.1 ml/kg/hr on each side.
Study: NCT02807727

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intralipid 20%
Description: Single intravenous bolus dose of 1.5 ml/kg over 3 minutes

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Modified Ringers Lactate
Description: Single intravenous bolus dose of 1.5 ml/kg over 3 minutes
Study: NCT02758938

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Urologic biofeedback software
Description: All subjects (end users) will be walked through the urologic biofeedback software training suite. Each end user will follow a protocol that is specific to their role. Upon completing their session(s) with the software, each end user will provide appropriate feedback.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Urologic biofeedback software
Description: All subjects (end users) will be walked through the urologic biofeedback software training suite. Each end user will follow a protocol that is specific to their role. Upon completing their session(s) with the software, each end user will provide appropriate feedback.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Urologic biofeedback software
Description: All subjects (end users) will be walked through the urologic biofeedback software training suite. Each end user will follow a protocol that is specific to their role. Upon completing their session(s) with the software, each end user will provide appropriate feedback.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Urologic biofeedback software
Description: All subjects (end users) will be walked through the urologic biofeedback software training suite. Each end user will follow a protocol that is specific to their role. Upon completing their session(s) with the software, each end user will provide appropriate feedback.
Study: NCT00582608

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 131I-8H9
Description: This is an open-label single arm study of 131I-8H9, injected intravenously at 10 mCi/1.73 m\^2 dose \[intended specific activity of \~20 mCi/mg protein\]

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 8H9
Description: administration of 50mg/1.73m\^2 of unlabeled 8H9.
Study: NCT01733667

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MediENT
Description: MediENT will be assigned to either the right or left side and positioned between the turbinate and nasal wall of the side assigned. MeroPack will be place in between the turbinate and nasal wall of the side not assigned to MediENT

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: MeroPack
Description: MediENT will be assigned to either the right or left side and positioned between the turbinate and nasal wall of the side assigned. MeroPack will be place in between the turbinate and nasal wall of the side not assigned to MediENT
Study: NCT03229252

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Inhalation Solution
Description: Normal Saline Inhalation Solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPX-101
Description: SPX-101 Inhalation Solution
Study: NCT03356938

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep restriction
Description: Restricted sleep to 5 hours / night for 5 days prior to sleep laboratory examination

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep deprivation
Description: Sleep deprivation during first night of sleep laboratory examination
Study: NCT03171038

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telemonitoring
Study: NCT05533008

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CR845 0.5 mcg/kg
Description: IV CR845 0.5 mcg/kg as a bolus injection

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: IV Placebo as a bolus injection
Study: NCT00820248

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: panitumumab
Description: Given IV
Study: NCT03229252

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPX-101
Description: SPX-101 Inhalation Solution
Study: NCT02473510

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trivalent Influenza Vaccine
Description: A single dose of 10\^(7.0 ± 0.5) FFU per strain of trivalent influenza vaccine will be administered as intranasal spray on Day 1.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A single dose of placebo matched to trivalent influenza vaccine will be administered as intranasal spray on Day 1.
Study: NCT00820248

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cisplatin
Description: Given IV

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: 3-dimensional conformal radiation therapy
Description: Patients undergo radiotherapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 3-dimensional conformal radiation therapy
Description: Patients undergo radiotherapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: accelerated radiation therapy
Description: Patients undergo accelerated fractionation radiotherapy

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: intensity-modulated radiation therapy
Description: Patients undergo radiotherapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: intensity-modulated radiation therapy
Description: Patients undergo radiotherapy
Study: NCT01980459

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: magnesium lactate
Description: Patient will be given 4 tablets a day of study supplement (Magnesium Lactate) for 3 months. Magnesium cellular and serum levels will be compared prior and post intervention.
Study: NCT01415713

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-1,Leucovorin,Oxaliplatin,Gemcitabine
Description: Biweekly S-1, Leucovorin, Oxaliplatin and Gemcitabine (SLOG) in metastatic pancreatic adenocarcinoma
Study: NCT03973879

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PVSRIPO
Description: Oncolytic polio/rhinovirus recombinant
Study: NCT01417897

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin glulisine
Description: Dosage will be pro re nata. Patients should aim an blood glucose level of 2h ppBG ≤ 135 mg/dL.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin aspart
Description: Dosage will be pro re nata. Patients should aim an blood glucose level of 2h ppBG ≤ 135 mg/dL.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Regular human insulin
Description: Dosage will be pro re nata. Patients should aim an blood glucose level of 2h ppBG ≤ 135 mg/dL.
Study: NCT03973879

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Antibody
Study: NCT03753464

Intervention type: PROCEDURE
Intervention: Gingival biopsy and blood sample collection
Description: Gingival and blood samples will be collected.

Intervention type: PROCEDURE
Intervention: Gingival biopsy and blood sample collection
Description: Gingival and blood samples will be collected.
Study: NCT02919319

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACT-541468 (Formulation A)
Description: Hard gelatin capsules for oral administration formulated at strengths of 5 mg, 25 mg and 100 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACT-541468 (Formulation A)
Description: Hard gelatin capsules for oral administration formulated at strengths of 5 mg, 25 mg and 100 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACT-541468 (Formulation A)
Description: Hard gelatin capsules for oral administration formulated at strengths of 5 mg, 25 mg and 100 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACT-541468 (Formulation A)
Description: Hard gelatin capsules for oral administration formulated at strengths of 5 mg, 25 mg and 100 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACT-541468 (Formulation A)
Description: Hard gelatin capsules for oral administration formulated at strengths of 5 mg, 25 mg and 100 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACT-541468 (Formulation B)
Description: Soft gelatin capsules for oral administration formulated at the strength of 25 mg
Study: NCT03745625

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HSK3486
Description: First-stage:after an initial dose of 1mg/kg/h, If the BIS is in the range of 80 to 60 and the continuous RASS score = 3 or one time RASS score ≤ -4, the 0.4 mg/kg/h maintenance dose is administered. The total infusion time was 4h.~Second-stage: a single loading dose of 0.2 mg/kg given over 1 minute, then a continuous infusion of maintenance dose 0.35 mg/kg/h for a total infusion time of 12h.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: First-stage: after an initial dose of 5mg/kg/h, If the BIS is in the range of 80 to 60 and the continuous RASS score = 3 or one time RASS score ≤ -4, the 0.4 mg/kg/h maintenance dose is administered. The total infusion time was 4h.~Second-stage: loading dose of 1mg/kg given over 1 minute, then a continuous infusion of maintenance dose 1.75 mg/kg/h for a total infusion time of 12h.
Study: NCT02919319

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (Formulation A)
Description: Hard capsules matching ACT-541468 Formulation A

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (Formulation A)
Description: Hard capsules matching ACT-541468 Formulation A

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (Formulation A)
Description: Hard capsules matching ACT-541468 Formulation A

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (Formulation A)
Description: Hard capsules matching ACT-541468 Formulation A

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (Formulation A)
Description: Hard capsules matching ACT-541468 Formulation A

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (Formulation B)
Description: Soft capsules matching ACT-541468 Formulation B

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 14C-labeled ACT-541468
Description: Tracer at a nominal dose of 250 nCi (corresponding to 2.02 µg ACT-541468) administered either orally or intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 14C-labeled ACT-541468
Description: Tracer at a nominal dose of 250 nCi (corresponding to 2.02 µg ACT-541468) administered either orally or intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo tracer
Description: Sterile NaCl 0.9% was used as placebo matching the tracer for oral and i.v. administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo tracer
Description: Sterile NaCl 0.9% was used as placebo matching the tracer for oral and i.v. administration.
Study: NCT02924285

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Procedure (Radiofrequency catheter ablation)
Description: Radiofrequency catheter ablation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amiodarone
Description: Amiodarone, Verification of superiority of catheter ablation over amiodarone for treatment of PVCs in patients with structural heart disease as:~Antiarrhythmic Drug Amiodarone
Study: NCT03138759

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pexidartinib
Description: Orally, on Day 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pexidartinib
Description: Orally, on Day 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Probenecid
Description: Orally, on Day 2
Study: NCT01636180

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: no repeated loading dose of clopidogrel with clopidogrel continuous therapy for 30 days (75 mg/day)
Study: NCT03138759

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Probenecid
Description: Orally, on Day 2
Study: NCT03232879

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motor Imagery
Description: Two consecutive 30 seconds imagery tasks were performed, both based on two movements that are recorded in the Revised Movement Imagery Questionnaire (MIQ-R).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Action Observation
Description: Two consecutive 30 seconds imagery tasks were performed, both based on two movements that are recorded in the Revised Movement Imagery Questionnaire (MIQ-R). Before the subjects performed the mental MI practice, they were presented with a 30 seconds video that displayed the task that they ought to imagine later. A video was played prior to the first practice of imagination and after the second mental practice, a second video was shown.
Study: NCT01046903

Intervention type: DRUG
Intervention: Fragmin® (Dalteparin Sodium)
Description: Administered per prescribing physician
Study: NCT02285166

Intervention type: DRUG
Intervention: Omega-3 fatty acid ethyl esters
Description: Omega-3 fatty acid ethyl esters granular capsules

Intervention type: DRUG
Intervention: Standard antihyperlipidemic therapy other than administration of omega-3 fatty acid ethyl esters (Lotriga).
Study: NCT05366348

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Recreational activity
Description: Horse-back riding
Study: NCT03110406

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: whole-body vibration training
Description: Training on the Vibrating platform will be performed with the patients in the static position.The exercises will be performed in the first two weeks for 10 minutes consisting of 60 seconds of low intensity and 30 seconds of standing rest in the anatomical position. From the second week to the end of the twelfth week (24 sessions) will be performed 15 minutes corresponding being 60 seconds of high intensity interspersed with 30 seconds of rest standing in the anatomical position. In the second month, the patient should be well adapted to the stimuli of the platform keeping the frequency of 35Hz and the amplitude 4mm. Monitoring of blood pressure, heart rate and peripheral oxygen saturation should be done every 5 minutes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: whole-body vibration training
Description: Training on the Vibrating platform will be performed with the patients in the static position.The exercises will be performed in the first two weeks for 10 minutes consisting of 60 seconds of low intensity and 30 seconds of standing rest in the anatomical position. From the second week to the end of the twelfth week (24 sessions) will be performed 15 minutes corresponding being 60 seconds of high intensity interspersed with 30 seconds of rest standing in the anatomical position. In the second month, the patient should be well adapted to the stimuli of the platform keeping the frequency of 35Hz and the amplitude 4mm. Monitoring of blood pressure, heart rate and peripheral oxygen saturation should be done every 5 minutes.
Study: NCT02097563

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High Intensity Training
Description: This is a training method involving a live workshop followed by high intensity technical consultation.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Low Intensity Training
Description: Clinicians complete an online workshop in family-focused therapy, followed by technical consultation sessions after every third session.
Study: NCT00616343

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zonisamide
Description: 100mg tablets once a day for two weeks, then increased to 200mg qhs for two weeks.
Study: NCT00300885

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nexavar (Sorafenib, BAY43-9006) + carboplatin + paclitaxel
Description: Chemotherapy Phase up to 6 cycles: Sorafenib (Nexavar, BAY43-9006), \[400 mg orally, twice daily\] on Study Days 2-19 and paclitaxel (P) (200 mg/m2, intravenous (IV)) and carboplatin (C) (area under the curve (AUC) =6 mg/ml\*min-1, IV) on Study Day 1. The cycle duration 21 days. Maintenance Phase: Sorafenib 400 mg orally twice daily was administered on Days 1-21 of each 21-day cycle.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin plus Paclitaxel
Description: Chemotherapy Phase up to 6 cycles: Sorafenib Placebo (2 tablets orally twice daily\] on Study Days 2-19 and paclitaxel (200 mg/m2, intravenous (IV)) and carboplatin (area under the curve (AUC) =6 mg/ml\*min-1, IV) on Study Day 1. The cycle duration 21 days. Maintenance Phase: Sorafenib Placebo 2 tablets orally twice daily was administered on Days 1-21 of each 21-day cycle.
Study: NCT00795470

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antimicrobial
Description: Appropriate antimicrobial based on urine culture results
Study: NCT04035590

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: No drain
Description: Mastectomy with flap fixation without low vacuum drainage
Study: NCT03954782

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nintedanib 150 mg and 100 mg soft capsules
Description: Nintedanib 150 mg soft capsules twice daily approximately 12 hours apart (i.e. 300 mg/day) for 12 weeks. In case of adverse reaction a dose reduction at 200 mg/day (100 mg twice daily) can be prescribe.
Study: NCT04035590

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: With drain
Description: Mastectomy with flap fixation with low vacuum drainage
Study: NCT00795470

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antimicrobial
Description: Appropriate antimicrobial based on urine culture results

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Catheter change
Description: Change urine catheter

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Catheter change
Description: Change urine catheter
Study: NCT03954782

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oral treatment of placebo soft capsule
Description: Placebo soft capsules (identical to 150 mg and 100 mg soft capsules)
Study: NCT04274673

Intervention type: DEVICE
Group type: OTHER
Intervention: measuring cotinine level
Description: Measuring of the cotinine levels
Study: NCT03157271

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intramuscular Dry Needling
Description: Dry Needling is a procedure in which a solid filament needle is inserted into the skin and muscle directly at a myofascial trigger point. A myofascial trigger point consists of multiple contraction knots, which are related to the production and maintenance of the pain cycle and interfere with movement patterns.